Clinical Trial Update: Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial) [Phase 2]

View source ↗

Summary

Phase 2 update on erdafitinib for FGFR-mutant relapsed or refractory pediatric cancers enrolled in the Pediatric MATCH trial; results were posted in 2024.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ependymoma
• Ewing Sarcoma
• Medulloblastoma
• Neuroblastoma
• Non-hodgkin Lymphoma
• Osteosarcoma
• Rhabdomyosarcoma
• Wilms Tumor

Drugs mentioned

• BALVERSA (erdafitinib)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Advanced Malignant Solid Neoplasm, Recurrent Childhood Ependymoma | Phase 2 | Status: ACTIVE_NOT_RECRUITING | Results posted: 2024-09-19